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Clostridium perfringens enterotoxin (CPE) can be used to eliminate carci-
noma cells that overexpress on their cell surface CPE receptors – a subset
of claudins (e.g., Cldn3 and Cldn4). However, CPE cannot target tumors
expressing solely CPE-insensitive claudins (such as Cldn1 and Cldn5). To
overcome this limitation, structure-guided modifications were used to gen-
erate CPE variants that can strongly bind to Cldn1, Cldn2 and/or Cldn5,
while maintaining the ability to bind Cldn3 and Cldn4. This enabled (a)
targeting of the most frequent endocrine malignancy, namely, Cldn1-over-
expressing thyroid cancer, and (b) improved targeting of the most common
cancer type worldwide, non-small-cell lung cancer (NSCLC), which is char-
acterized by high expression of several claudins, including Cldn1 and
Cldn5. Different CPE variants, including the novel mutant CPE-Mut3
(S231R/S313H), were applied on thyroid cancer (K1 cells) and NSCLC
(PC-9 cells) models. In vitro, CPE-Mut3, but not CPEwt, showed Cldn1-
dependent binding and cytotoxicity toward K1 cells. For PC-9 cells, CPE-
Mut3 improved claudin-dependent cytotoxic targeting, when compared to
CPEwt. In vivo, intratumoral injection of CPE-Mut3 in xenograft models
bearing K1 or PC-9 tumors induced necrosis and reduced the growth of
both tumor types. Thus, directed modification of CPE enables eradication
of tumor entities that cannot be targeted by CPEwt, for instance, Cldn1-
overexpressing thyroid cancer by using the novel CPE-Mut3.
1. Introduction
Thyroid cancer is the most common endocrine malig-
nancy. Papillary thyroid carcinoma (PTC), a differentiated
type of thyroid cancer, is the most common histological
subtype accounting for approximately 70% of thyroid
cancer cases (Wartofsky, 2010). Often, surgery is the most
successful treatment for PTC patients and is normally
Abbreviations
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associated with a good prognosis. However, approxi-
mately 20–25% of patients develop distant metastases
(most in lung and bone) of PTC and have a worse progno-
sis, since advanced PTC often does not respond to con-
ventional radioactive iodine therapy (radioactive iodine
refractory thyroid cancer).
Lung cancer (both small-cell and non-small-cell lung
cancer – NSCLC) is the most common cancer (80–
85% of all cases) and is the most common cause of
death from cancer worldwide. In addition, approxi-
mately 50–70% of patients with lung adenocarcinoma,
one type of NSCLC, after surgery relapse within one
year and their cancer cells acquire a chemoresistant
phenotype (Ramalingam and Belani, 2008). Targeted
drugs, such as angiogenesis inhibitors, epidermal
growth factor receptor inhibitors, anaplastic lym-
phoma kinase inhibitors, and immunotherapy drugs,
that act via T cells, eventually can shrink tumors for
several months only and are associated with side
effects (Silva et al., 2017). Therefore, treatment of
radioiodine refractory thyroid cancer and chemoresis-
tant NSCLC remains challenging and new targets and
therapeutic substances are desperately needed.
One promising strategy for targeted cancer therapy
is delivery of foreign toxic molecules specifically to
tumor cells (Walther et al., 2012). Bacterial toxins, as
attractive candidates, demonstrated efficient cell-killing
capacity in several in vitro and in vivo studies (Dang
et al., 2001; Michl and Gress, 2004; Morin, 2005).
Employment of pore-forming bacterial toxins, such as
Clostridium perfringens enterotoxin (CPE) (Minton,
2003; Walther et al., 2012), enables specific targeting
of their receptors, which are frequently expressed on
cancer cells’ surface. Thereby, the strategy has a great
potential to target cancer cells, while minimizing side
effects on normal cells.
Clostridium perfringens enterotoxin, mainly associ-
ated with food poisoning, is released by anaerobic
Gram-positive C. perfringens type A strains. CPE is a
b-pore-forming toxin, consisting of 319 amino acids
(35 kDa) and two functional domains with a known
structure (pdb: 2XH6, Briggs et al., 2011, pdb: 3AM2,
Kitadokoro et al., 2011). CPE-mediated cytotoxicity
has been studied and described thoroughly. The proce-
dure starts with CPE binding to its receptors (claudins)
on the plasma membrane via its C-terminal domain
(cCPE) (McClane, 2001; Veshnyakova et al., 2010),
whereas the N-terminal domain inserts into membrane
and participates in cytotoxic pore formation allowing
rapid Ca2+-influx leading to cell death (Chakrabarti
and McClane, 2005; Eichner et al., 2017). In contrast
to full length CPE, the C-terminal domain of CPE
(amino acids 194–319, cCPE) is not toxic (Kokai-Kun
and McClane, 1997), but maintains binding to claudins
(McClane, 2001). Claudins (Cldn, 27 family members)
constitute tight junctions (TJs) which regulate paracel-
lular permeability across epithelia. CPE interacts only
with a subset of claudins. It binds with high affinity
(Kd ~ 10 nM) to Cldn3, Cldn4, Cldn6, Cldn7, and
Cldn9; with medium affinity to Cldn8, Cldn14, and
Cldn19; and with low affinity to Cldn1 and Cldn2, but
does not bind to Cldn5, Cldn10 to Cldn13, Cldn15 to
Cldn18, and Cldn20 to Cldn24 (Bocsik et al., 2016;
Veshnyakova et al., 2010).
In carcinoma cells, claudins are usually mislocalized
out of TJs (extrajunctional) and often deregulated
(Kwon, 2013), thereby not necessarily contributing to
TJ sealing and paracellular barrier regulation. Many
epithelial tumors exhibit increased claudin expression
(Kominsky et al., 2004; Long et al., 2001; Lu et al.,
2013; Michl et al., 2001; Santin et al., 2007; Soini and
Talvensaari-Mattila, 2006), which has been discussed
as potential marker in oncology (Long et al., 2001).
Claudin upregulation is assumed to benefit tumor pro-
gression by promoting cell migration, invasion, and
metastasis (Jian et al., 2015). In addition to such aber-
rant expression, extrajunctional mislocalization of
claudin proteins may contribute to their role in
tumorigenesis (Boireau et al., 2007).
In case of thyroid cancer (Zwanziger et al., 2015)
and NSCLC, overexpression (Jung et al., 2009; Sun
et al., 2016) and extrajunctional mislocalization of
Cldn1, with impact on cell–cell contacts and prolifera-
tion, is a specific hallmark. Expression of Cldn1 was
demonstrated in PTC, papillary microcarcinoma pri-
mary tumors, and lymph node metastases (Nemeth
et al., 2010) and is assumed to be a prognostic factor
for patients with lung adenocarcinoma (Sun et al.,
2016). This makes Cldn1 a promising target for thera-
peutic approaches.
Several studies have suggested CPE as a biologic for
treatment of tumors overexpressing claudins (Black
et al., 2015; Kominsky et al., 2007; Morin, 2007; Vesh-
nyakova et al., 2010). Dependence of CPE-mediated
cytotoxicity on expression of CPE-sensitive claudins
was shown in numerous studies (Eichner et al., 2017;
Fujita et al., 2000; Robertson et al., 2010; Sonoda
et al., 1999), including claudin knockdowns (Casa-
grande et al., 2011; Pahle et al., 2017; Tanaka et al.,
2018).
However, employment of wild-type CPE (CPEwt)
for cancer treatment is restricted to carcinomas, which
express CPEwt-binding claudins (e.g., Cldn3, Cldn4).
In addition, extrajunctional CPE-sensitive claudin
molecules are also present on normal epithelia, at least
to a minor extent. This can result in side effects during
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CPE treatment. To overcome these difficulties, we
modified CPE for the first time to adjust its claudin-
binding properties to the claudin expression profile of
certain cancer types containing claudin subtypes that
are not bound by CPEwt.
Here, we demonstrate expansion of CPE-based
oncoleaking strategy specifically for tumor types overex-
pressing claudins, which are not CPE receptors such as
Cldn1 by design and use of CPE mutants: In vitro and
in vivo, tumor growth of PTC (K1 cells), overexpressing
mainly Cldn1, but not Cldn3 and Cldn4, was efficiently
reduced by Cldn1-binding CPE-variant S231R/S313H
(CPE-Mut3), but not by CPEwt. In addition, we show
that CPE variants suppress growth of NSCLC tumors
in a claudin-directed manner.
2. Materials and methods
2.1. Plasmids
Plasmid encoding pGEX-4T-CPE194-319 carrying
cCPE with N-terminal GST-fusions was described
(Veshnyakova et al., 2012b). Single or multiple substi-
tutions (N218Q, S231R, K283R, S305P, Y306A,
Y306W, S307R, S313H, and L315A) were generated
by site-directed mutagenesis of pGEX-4T1-CPE194-
319, as described earlier (Winkler et al., 2009).
For expression as N-terminal 6xHis-fusion, CPE
cDNA was subcloned from vector pCpG-optCPE
(Walther et al., 2012) as described earlier (Eichner et al.,
2017). Site-directed mutagenesis to generate full lengths
CPE-Y306A/L315A (negative control), CPE-S313H
(Mut1), CPE-S231R (Mut2), CPE-S231R/S313H
(Mut3), CPE-S305P/S307R/S313H (Mut4), CPE-
S231R/Y306W/S313H (Mut5), CPE-N218Q/Y306W/
S313H (Mut6), CPE-N218Q/S231R/S313H (Mut7),
CPE-N218Q/S231R/Y306W/S313H (Mut8), and CPE-
Y306W/S313H (Mut9) was performed as described
(Winkler et al., 2009). Plasmids based on pEYFP-N1
encoding human Cldn1-YFP, Cldn2-YFP, Cldn5-YFP,
Cldn6-YFP, Cldn7-YFP, murine Cldn3-YFP, as well as
plasmid pEGFP-Cld4 encoding human Cldn4 with
N-terminal GFP (Protze et al., 2015) and plasmid
encoding human Cldn1 with N-terminal FLAG
(Veshnyakova et al., 2012a) have been described previously.
2.2. Expression and purification of cCPE and CPE
constructs
GST-cCPE constructs were expressed and purified as
described (Protze et al., 2015). Labeling according to
Table S1.
6xHis-CPE was expressed in Escherichia coli TOP10
(Thermo Fisher Scientific, Waltham, MA, USA) and
purified from lysates using Ni-NTA-Agarose (Qiagen
GmbH, Hilden, Germany), as described earlier (Eich-
ner et al., 2017). For negative control, preparations
from bacteria transformed with vector containing CPE
insert in antisense – and thus not expressing any CPE
– were carried out in parallel, as described earlier
(Eichner et al., 2017).
2.3. Cell culture
All cell lines were purchased from Sigma-Aldrich
(Taufkirchen, Germany). Native HEK293 (HEK) cells
and HEK cells, stably transfected with Cldn1-7, were
cultured as described elsewhere (Protze et al., 2015).
PC-9 and Nthy-ori 3-1 cells were cultivated in RPMI
(10% FBS; 1% penicillin/streptomycin, P/S), K1 – in
DMEM (10% FBS; 1% P/S), and SK-Mes-1 – in
MEM (10% FBS; 1% P/S, 1% nonessential amino
acids) and were grown in a 5% CO2 atmosphere at
37 °C.
2.4. CPE transfection
When cells seeded on poly-L-lysine (Sigma-Aldrich, St.
Louis, MO, USA) precoated 96-well plates reached
80% confluency, they were transiently transfected with
0.1 µg DNA of CPE constructs and vector with anti-
sense CPE sequence (as negative control) using Via-
Fect (Promega, Madison, WI, USA).
2.5. MTT cytotoxicity assay
For MTT ((3-4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide; Sigma-Aldrich, USA) cytotoxicity
assay cells were seeded 80% confluent on 96-well
plates (Sigma-Aldrich, USA) precoated with poly-L-ly-
sine. On next day, cells were preincubated at 37 °C,
5% CO2 for 1 or 24 h, with variable dilutions of cCPE
or CPE preparations or 0.01% (v/v) Triton X-100
(background correction) before medium was replaced
by medium without phenol red containing 1.25 mM
MTT. Two hours later, cells were treated with 5% (v/
v) Triton X-100 in 2-propanol for 20 min and absorp-
tion was measured at 560 nm.
2.6. Cellular binding assay
Native claudin-negative HEK cells are a suitable
model to test specific targeting of single claudins, when
those are expressed exogenously (Protze et al., 2015).
Two days after transient transfection or 1 day after
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plating of stable lines, HEK cells expressing one of the
tested claudins (Cldn1-7) were incubated with
0.5 µgmL1 GST-cCPE constructs (30 min, 37 °C) in
24-well plates (Sigma-Aldrich, USA). Amount of
bound cCPE was detected as described elsewhere
(Protze et al., 2015).
2.7. Cell lysis and western blotting
K1, Nthy-ori 3-1, PC-9, and SK-Mes-1 cells were
seeded in 25 cm2 cell culture flasks (Greiner Bio One,
Kremsmuenster, Austria). After reaching confluency,
cells were washed and harvested, and extracted mem-
brane protein fraction was analyzed as described else-
where (Veshnyakova et al., 2012a). Proteins were
detected using specific antibodies against Cldn1-9 or
with anti-b-actin (Thermo Fisher Scientific), respec-
tively, and visualized by luminescence imaging (Lumi-
Imager, Roche, NY, USA).
2.8. Structural bioinformatics and molecular
modeling
Homology models of claudin–cCPE complexes were
built based on Cldn4–cCPEwt complex (PDB ID:
5B2G, Shinoda et al., 2016). All manipulations, opti-
mizations of models, were handled as described else-
where (Neuhaus et al., 2018).
2.9. In vivo CPE application
For cell line-derived subcutaneous xenotransplant
(CDX) tumor models, 5 9 105 PC-9 cells or 1 9 106 K1
cells were injected subcutaneously into female NOG
mice (n = 5 animals per group). Tumor volume (TV,
calculated according to formula 0.5 9 length 9 width2)
and body weight were determined at least twice weekly.
When tumors reached mean volume of 0.14–0.17 cm3,
recombinant CPE was injected intratumorally in anes-
thetized animals. In total, 20 lg of recombinant CPE
was applied by 10 injections (daily dose of 0.04 lg
CPElL1 0.9% NaCl). During treatment, TV was mea-
sured at days 11, 14, 18, and 21 after injection of PC-9
cells or at days 18, 21, 25, and 28 after injection of K1
cells. Animals were sacrificed for tumor removal and
further analysis. All experiments were performed at
EPO GmbH, Berlin, Germany.
2.10. Solid tumor tissue dissection
Shock frozen tumor tissues were fixed with Tissue-Tek
Medium (Sakura, Staufen, Germany) and dissected
with cryostat into cryosections each of 10 or 18 lm
thickness, which were transferred onto cover slides.
2.11. Hematoxylin and eosin staining
For morphological evaluation of 18 µm thick tissue
sections, hematoxylin and eosin (HE) staining was per-
formed. Staining procedures were performed by stan-
dard protocols (Fischer et al., 2008). All samples were
digitally scanned and viewed using Aperio ScanScope
AT2 system (Leica Biosystems, Wetzlar, Germany)
and QUPATH software (Bankhead et al., 2017). Necrotic
areas were calculated by determination of the whole
tissue area vs necrotic tissue area using IMAGEJ (open
source software, https://imagej.net/) in triplicates of
two samples per group. Necrotic area in % related to
the whole tissue area is shown.
2.12. Immunohistochemistry of human thyroid
samples
Thyroid samples were obtained from patients undergoing
thyroid surgery for PTC. For Cldn1 staining, paraffin-em-
bedded tissue sections of 10 PTC were studied. Classifica-
tion of thyroid nodules was performed by pathologists
according to World Health Organization criteria. Cldn1
staining with anti-Cldn1 antibody was performed as
described previously (Zwanziger et al., 2015). All samples
were digitally scanned and viewed using Aperio ScanScope
AT2 system and QUPATH software.
2.13. Statistics
Data are expressed as mean  SEM. Statistical analyses
were performed with GRAPHPAD PRISM version 5.0 (San
Diego, CA, USA) using one-way or two-way ANOVA
and Bonferroni’s adjustment for multiple comparisons.
3. Results
3.1. Generation of cCPE variant with improved
Cldn1 binding
We first aimed to create variants of the nontoxic clau-
din-binding domain of CPE (cCPE) with increased
Cldn1 binding. Mutation S313H in cCPE, was previ-
ously shown to improve Cldn1 binding and enable
Cldn5 binding (Protze et al., 2015; Takahashi et al.,
2012).
To further improve Cldn1 and Cldn5 binding of
cCPE-Mut1 (cCPE-S313H), we generated models of
claudin–cCPE-S313H interaction (Fig. 1A–C). This
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pointed us to substitution of S231 to Arg to poten-
tially enhance Cldn1- (Fig. 1B) and Cldn5 binding
(Fig. 1C). According to our models, S231R in cCPE
(cCPE-Mut2) should allow formation of hydrogen
bonds with Q146 and E147 in Cldn1 improving Cldn1-
binding properties of cCPE (Fig. 1B) and with E76
and E146 enabling interaction with Cldn5 (Fig. 1C).
Furthermore, it potentially enhances binding to Cldn2
by interacting with D76 which corresponds to E76 in
Cldn5.
In sum, molecular models suggests that mutation
S231R increases the interaction with Cldn1 and Cldn5.
Mutants that previously showed effects on interaction
with Cldn1 and Cldn5 (N218Q, Neuhaus et al., 2018;
Y306W and S313H, Protze et al., 2015) were here
tested in the following combinations: The model-
guided recombinant cCPE variants Mut1 (cCPE-
S313H), Mut2 (cCPE-S231R), Mut3 (cCPE-S231R/
S313H), Mut5 (S231R/Y306W/S313H), Mut6 (N218Q/
Y306W/S313H), Mut7 (N218Q/S231R/S313H), Mut8
(N218Q/S231R/Y306W/S313H), Mut9 (cCPE-Y306W/
S313H), and negative control (cCPE-Y306A/L315A)
not binding to claudins (Protze et al., 2015; Table S1)
were expressed in E. coli, and purified as previously
reported (Protze et al., 2015; Veshnyakova et al.,
2012b). Binding of these cCPE variants toward Cldn1
was tested on HEK cells transiently transfected with
Cldn1-YFP (Fig. 2A). Single substitutions Mut1 and
Mut2 significantly enhanced binding toward Cldn1
and boosted it further, when combined in double
mutant Mut3. Moreover, combining single mutation
Mut2 with other double mutations resulting in triple
mutations cCPE-Mut5 or cCPE-Mut7 increased bind-
ing to Cldn1, too. Four substitutions (cCPE-Mut8)
showed intermediate effect. Mut6 was employed as
additional negative control, since it is known to
decrease Cldn1 binding, but to increase Cldn5 binding
of cCPE (Neuhaus et al., 2018). In summary, the data
showed that cCPE-Mut3 has the best binding proper-
ties toward Cldn1.
To test whether cCPE candidate mutations (Mut3
and related Mut1/Mut2, Table S1) influence binding
properties toward other claudins, HEK cells stably
expressing YFP-tagged single claudins (Cldn1, Cldn2,
Cldn3, Cldn5, Cldn6, or Cldn7) or GFP-tagged Cldn4
were employed in cellular binding assay. The YFP- or
GFP-tag located intracellularly did not influence the
extracellular interaction between claudins and cCPE
variants (Veshnyakova et al., 2012b; Winkler et al.,
2009). As predicted by modeling, compared to
cCPEwt, cCPE-Mut3 bound significantly stronger to
Cldn1, Cldn2, and Cldn5 (Fig. 2B,C,F), but weaker
to Cldn4 and Cldn6 (Fig. 2E,G). There was no change
in binding to Cldn3 (Fig. 2D).
Fig. 1. Predicted interaction of cCPE-Mut3 with Cldn1 and Cldn5. (A) Extracellular domains (ECL1 and ECL2) of Cldn1 (green) interact with
CPE residues, both within ECL2-binding pocket (blue dashed line, Protze et al., 2015) and outside of it. Modeling of Cldn1-CPE interaction
interface (based on Cldn4-cCPEwt complex, PDB ID: 5B2G, Shinoda et al., 2016) suggested the highlighted mutations (Mut1, blue; Mut2,
red) on the cCPE surface (gray) to improve binding. (B) Close up view of modeled interaction between Cldn1 and cCPE-Mut3. (C) Close up
view of modeled interaction between Cldn5 and cCPE-Mut3.
265Molecular Oncology 14 (2020) 261–276 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A. Piontek et al. Targeting thyroid & lung cancer by modified enterotoxin
3.2. CPE-Mut3 enables Cldn1-directed
cytotoxicity
Next, substitutions Mut1 and Mut2 were introduced into
His-tagged full length CPE resulting in CPE-Mut3 to
investigate its Cldn1-related cytotoxicity. For compar-
ison, Mut4 (S305P/S307R/S313H), previously shown to
increase binding of cCPE to Cldn1 and other claudins,
similar as S313H (Protze et al., 2015; Takahashi et al.,
2012), was also introduced into full length CPE. CPEwt,
CPE-Mut3, CPE-Mut4, and CPE-negative control
(Y306A/L315A, not interacting with claudins, Eichner
et al., 2017) were applied to nontransfected and stably
Cldn1-FLAG-transfected HEK cells. Nontransfected
HEK cells were insensitive to any of the tested full length
CPE variants (Fig. 3A). In contrast, Cldn1-FLAG-
expressing HEK cells were highly sensitive to CPE-Mut3,
which strongly reduced cell viability already at low con-
centrations (0.2 µgmL1, Fig. 3B). The broad specificity
binder CPE-Mut4 had to be applied in 10-fold higher
concentrations – 2 µgmL1 to be as cytotoxic as CPE-
Mut3 (Fig. 3B). CPEwt or CPE-negative control did not
reduce cell viability for Cldn1-FLAG-expressing HEK
cells significantly.
Thus, CPE-Mut3, but not other CPE variants,
enables efficient Cldn1-directed cytotoxicity. Similarly,
structure-based mutagenesis of CPE was used to
enable Cldn5-directed cytotoxicity or to narrow down
cytotoxicity toward Cldn4 (Fig. S1). Mechanistically,
these CPE variants mediate cytotoxicity as CPEwt by
induction of Ca2+-influx (Fig. S2).
3.3. Expression of endogenous claudins in PTC
and NSCLC cell models
We aimed to test cytotoxicity of Cldn1-binding CPE
variants on thyroid and lung cancer cell lines, such as
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Fig. 2. Double mutation S231R/S313H (Mut3) increases claudin
binding of cCPE. (A) Binding assays with transiently Cldn1-
transfected HEK cells revealed that cCPE-Mut3 is the strongest
interaction partner of Cldn1 in comparison with the other cCPE
variants. Binding assays with HEK cells stably transfected with
Cldn1-YFP (B), Cldn2-YFP (C) Cldn3-YFP (D), Cldn4-GFP (E), Cldn5-
YFP (F), Cldn6-YFP (G), or Cldn7-YFP (H) showed that cCPE-Mut3
binds stronger to Cldn1, Cldn2, and Cldn5, then cCPEwt. Similarly
to Cldn1-transfected HEK cells, binding assays with PTC model cell
line K1 cells and Nthy-ori 3-1 (Nthy-ori) thyroid follicular epithelial
cells (I) showed strongest binding for cCPE-Mut3. cCPE bound
stronger to K1 than to Nthy-ori cells. (J) cCPE-Mut3 and cCPEwt
bound stronger than cCPE-negative control to PC-9 and SK-MES-1
cells. cCPE-Mut3 and cCPEwt bound stronger to PC-9 than to SK-
MES-1 cells. Cells were incubated for 30 min with different GST-
cCPE constructs (0.5 µgmL1), washed, and the bound cCPE
was detected via anti-GST-R-phycoerythrin antibodies. The signal
was normalized to cell number (A, I, J) or claudin expression level
(B-H, YFP- or GFP signal), and the binding of cCPE mutants relative
to cCPEwt was calculated. One-way ANOVA, * vs cCPEwt or as
indicated, ● vs cCPE-negative control, □ vs treatment in low
claudin-expressing cells (K1 vs Nthy-ori and PC-9 vs SK-MES-1,
respectively). n ≥ 3. *, P < 0.05; **, □□, P < 0.01; ***, ●●●
P < 0.001; ****, ●●●●, □□□□, P < 0.0001.
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K1 cells (PTC) and Nthy-ori 3-1 cells (transformed
from normal human thyroid follicular epithelial cells),
PC-9 (lung adenocarcinoma), and SK-Mes-1 (lung
squamous-cell carcinoma). Expression of Cldn1, as
well as of other claudins (Cldn2 to Cldn9), in these cell
lines was analyzed by western blot (Fig. 4A). For K1
and Nthy-ori 3-1 cells, expression analysis (Fig. 4A)
revealed predominant Cldn1 expression with higher
Cldn1 expression in K1 cells. This claudin expression
matched to the one in human PTC tissue for which
pronounced plasma membrane staining of Cldn1 was
observed (Fig. 4B). In normal human thyroid tissue,
Cldn1 was moderately expressed in plasma membrane
and cytoplasm (Fig. 4C; Zwanziger et al., 2015).
Tested lung cancer cell lines expressed not only Cldn1,
but also Cldn3, Cldn4, and Cldn7 (PC-9 cells) or
Cldn3 (SK-Mes-1 cells).
Since Cldn1 expression in PC-9 cells was higher than
that of SK-Mes-1 cells, PC-9 cells were used as model
for NSCLC for further experiments. K1 cells were
chosen as model for PTC and Nthy-ori 3-1 cells as
thyroid follicular epithelial cell model.
3.4. CPE-Mut3 reduces cell viability of thyroid
cancer cells in vitro
First, we tested binding of nontoxic cCPE variants to K1
and Nthy-ori 3-1 cells expressing Cldn1. Similarly as
found for HEK-Cldn1 cells (Fig. 2A), cCPE-Mut3 bound
stronger than other cCPE variants to both cell lines
(Fig. 2I). Furthermore, stronger binding of cCPE-Mut3
(relative to cCPEwt) to K1 compared with Nthy-ori 3-1
cells correlated with higher Cldn1 expression in K1 cells
(Fig. 4A). The data showed that Mut3 enables binding of
cCPE to Cldn1-expressing thyroid cancer cells.
Consequently, cytotoxicity of full length CPE-Mut3
was tested on Nthy-ori 3-1 and K1 cells using MTT
assays. After 24-h incubation with CPEwt, CPE-nega-
tive control, CPE-Mut3, and CPE-Mut4, viability of
Nthy-ori 3-1 cells was not affected (Fig. 5A). In con-
trast, incubation of K1 cells with the Cldn1-binders
CPE-Mut3 and CPE-Mut4 (Fig. 5B, green and pink)
reduced cell viability. At highest concentration, CPE-
Mut3 reduced K1 cell viability remarkably to about
20% of negative control levels, whereas CPE-Mut4
decreased it to about 80% of control levels, only. The
CPE-negative control and CPEwt (Fig. 5B, black) did
not have any toxic effect on K1 cells.
To further verify that CPE-mediated cytotoxicity
depends on presence of claudins on surface of K1 cells,
K1 cells were incubated simultaneously with both non-
cytotoxic cCPE (wt or Mut3) and cytotoxic full length
CPE-Mut3 in same molar concentrations. cCPE-Mut3
bound to Cldn1 on the surface of K1 cells and thereby
protected them completely from cytotoxic effect of full
length CPE-Mut3 (Fig. 5B, blue). In contrast, due to
poor interaction of CPEwt with Cldn1, it could not
fully protect K1 cells from CPE-Mut3-mediated cyto-
toxicity (Fig. 5B, orange).
Thus, unlike CPEwt and the broad specificity binder
CPE-Mut4, the designed CPE-Mut3 strongly reduced
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Fig. 3. Cytotoxicity of CPE variants toward Cldn1-expressing HEK
cells depends on their Cldn1-binding ability. Nontransfected (A) or
stably Cldn1-FLAG-transfected HEK cells (B) were exposed to full
length CPE variants applied at different concentrations (0.02–
2.0 µgmL1) for 24 h, 37 °C. MTT cytotoxicity assay revealed that
only Cldn1-transfected cells were sensitive to CPE variants. CPE-
Mut3 and CPE-Mut4 but not CPEwt or CPE-negative control
reduced cell viability considerably. Strikingly, CPE-Mut3 was
cytotoxic at much lower concentration (0.2 µgmL1, green dotted
line) than CPE-Mut4 (2.0 µgmL1 magenta dotted line). Growth
medium with 0.1% Triton X-100 was used as control for cell lysis.
n = 3. Two-way ANOVA with Bonferroni multiple comparisons.
***P < 0.001; ****P < 0.0001 significant vs wt (at the same
concentration).
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cell viability selectively in K1 cells overexpressing
Cldn1 (in vitro PTC model). The insensitivity of Nthy-
ori 3-1 cells to CPE-Mut3 is likely due to their low
Cldn1 expression and suggests that CPE-Mut3-medi-
ated cytotoxicity could potentially be restricted to Cld-
n1-overexpressing malignant PTC.
3.5. CPE variants are cytotoxic for PC-9 lung
cancer cells
Similar as for thyroid follicular epithelia and PTC
cells, we tested binding of nontoxic cCPE variants to
PC-9 and SK-MES-1 lung cancer cells. cCPEwt and
cCPE-Mut3 bound much stronger to PC-9 cells than
the cCPE-negative control (Fig. 2J). cCPEwt and
cCPE-Mut3 bound stronger to PC-9 cells than to SK-
MES-1 cells. Nevertheless, cCPE-Mut3 bound stronger
than cCPEwt and the latter stronger than the cCPE-
negative control to SK-MES-1 cells (Fig. 2J). cCPE
binding to the different cell lines correlates to their
respective claudin expression profile and level
(Fig. 4A).
To investigate the cytotoxic effect of CPE vari-
ants on lung cancer cells, SK-MES-1 and PC-9
cells were incubated with CPE variants for 1 h. In
contrast to the CPE-negative control, CPEwt and
Fig. 4. Claudin expression profile of thyroid and lung cancer cells. (A) The expression of endogenous Cldn1 to Cldn9 (20–22 kDa) in human
PTC (K1 cells) and thyroid follicular epithelial Nthy-ori 3-1 cells (Nthy-ori) as well as in human lung AC (PC-9 cells) and squamous-cell
carcinoma (SK-Mes1 cells) was analyzed by western blot. Equal loading of each lane was verified by b-actin detection. n = 3. (B)
Immunohistochemical analysis of Cldn1 in PTC. Strong Cldn1 plasma membrane staining in PTC. Representative photomicrographs are
shown. n = 10. Scale bar 100 µm (left) and 50 µm (right). (C) Immunohistochemical analysis of Cldn1 in normal thyroid tissue.
Representative photomicrograph is shown. n = 3. Scale bar 100 µm.
Fig. 5. Claudin-binding CPE variants are highly cytotoxic for K1 thyroid and PC-9 lung carcinoma cells. Viability of Nthy-ori 3-1 cells (Nthy-ori)
(A) and K1 cells (B) 24 h after application of CPE variants at different concentrations. For Nthy-ori 3-1 cells weakly expressing Cldn1, none
of the treatments reduced cell viability. For K1 cells strongly expressing Cldn1, CPE-Mut3 drastically reduced cell viability. Cells were either
incubated with CPEwt, CPE-negative control, CPE-Mut3, or CPE-Mut4 or simultaneously treated with cCPEwt or cCPE-Mut3 and CPE-Mut3.
Afterward, MTT assay was performed. In competition assay, simultaneous incubation with both nontoxic cCPE-Mut3 and full length CPE-
Mut3 (blue line) protected K1 cells from CPE-Mut3-mediated cytotoxicity (green line). cCPEwt added together with CPE-Mut3 (orange line)
showed just a weak protective effect, and CPE-negative control (purple line) and CPEwt (black line) did not affect K1 cells. (C) SK-MES-1
cells were incubated for 1 h with CPE variants (wt, Mut3 and negative control) at different concentrations followed by MTT assay. CPEwt
and CPE-Mut3 reduced cell viability to ~ 50%. (D) PC-9 cells expressing multiple claudins were efficiently attacked by CPEwt, CPE-Mut3,
and CPE-Mut4. Cells were incubated for 1 h with CPE variants (wt, Mut3, Mut4, and negative control) at different concentrations followed
by MTT assay. Where indicated, cells were preincubated for 1 h with nontoxic cCPE (wt or Mut3) before CPE-Mut3 application. Partial
inhibition effect at concentrations lower than 0.2 µgmL1 and full inhibition at higher concentrations (blue, orange lines) indicated that low
cCPE concentration was not sufficient to occupy all CPE receptors. (E) PC-9 cells were transfected with DNA (0.1 µg) of CPE constructs,
and 24 h later, MTT cytotoxicity assay was performed. All CPE constructs, except for CPE-negative control, were toxic similarly to 0.1%
Triton X-100. Application of growth medium with 0.1% Triton X-100 was used as control for cell lysis in (A–E). n = 3–11 (K1 cells + Mut4
n = 1), one-way ANOVA with Bonferroni multiple comparisons significant vs CPE-negative control (at the same concentration) **P < 0.01;
***P < 0.001; ****P < 0.0001 (A–D), or one-way ANOVA with Bonferroni multiple comparisons significant vs ViaFect, (n = 4) *P < 0.05;
**P < 0.01; ***P < 0.001 (E).
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Mut3 decreased cell viability of SK-MES-1 cells
at concentrations ≥ 0.1 µgmL1 (Fig. 5C). For
PC-9 cells expressing multiple claudins (Fig. 4A)
and showing strong cCPE binding, incubation
with CPEwt, Mut3, and Mut4 strongly decreased
cell viability at concentrations ≥ 0.1 µgmL1
(Fig. 5D, green dotted line). At concentra-
tions ≥ 1 µgmL1, these CPE variants reduced
cell viability similarly to the level of cell lysis pos-
itive control (0.1% Triton X-100, about 20%,
Fig. 5D, magenta dotted line). As expected, CPE-
negative control did not reduce cell viability even
at high concentrations. The stronger CPE sensitiv-
ity of PC-9 compared to SK-MES-1 cells corre-
lated to their claudin expression profiles and
levels (Fig. 4A).
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Competition cytotoxicity assay with nontoxic cCPE
variants demonstrated that full length CPE-Mut3
requires claudin molecules on the plasma membrane.
PC-9 cells were preincubated with cCPEwt or cCPE-
Mut3 for 1 h before 1-h incubation with the same
molar concentration of full length CPE-Mut3. Preincu-
bation of PC-9 cells with cCPEwt or cCPE-Mut3 led
to competition for claudin binding and at high concen-
trations strongly inhibited reduction in cell viability
mediated by CPE-Mut3 (Fig. 5C, blue and orange),
indicating that protective effect of cCPE depends on
its concentration. Thus, CPE-Mut3-mediated cytotoxi-
city depends on claudins on the surface of PC-9 cells.
The data showed that claudin-binding CPE variants
can efficiently attack lung cancer cells expressing mul-
tiple claudins.
3.6. CPE application via DNA transfection
As an alternative application route, CPE transfection
(Walther et al., 2012) was used for comparison.
0.1 µg DNA of CPE constructs or controls were
transiently transfected into PC-9 cells, and 24 h later,
cytotoxicity assay was performed. MTT assays
revealed similar results as with recombinant CPE:
CPEwt, CPE-Mut3, and CPE-Mut4, but not the
nonbinding CPE-negative control strongly reduced
cell viability (Fig. 5E). Our data support the rigorous
claudin dependency of CPE toxicity independently of
the route of application as shown before (Walther
et al., 2012).
Thus, two independent approaches of CPE applica-
tion (recombinant protein and DNA transfection)
demonstrated for PC-9 cells (a) claudin-dependent
cytotoxicity of CPE and (b) that all claudin-sensitive
CPE variants (CPEwt, CPE-Mut3 and CPE-Mut4)
reduced cell viability. The latter can be explained by
the fact that PC-9 cells do not only express Cldn1, but
also Cldn3, Cldn4, and Cldn7 (Fig. 4A), which
strongly interact with CPEwt and CPE-Mut4.
3.7. CPE treatment reduces tumor growth of
thyroid and lung cancer in vivo
Finally, we tested in vivo the effect of CPE variants on
tumor growth on CDX models. For establishment of
subcutaneous tumors, K1 or PC-9 cells were injected
into female NOG mice. When tumors reached a mean
volume of 0.14–0.17 cm3, 10 intratumoral injections of
recombinant CPE (wt or -Mut3) or of vector control
preparations were administrated within 10 days (single
2 µg injection daily).
In the PTC K1 xenograft model, during treatment
by vector control and CPEwt the tumor was growing
strongly to 1.1  0.15 cm3 and to 1.0  0.21 cm3,
respectively. In contrast, for CPE-Mut3-treated ani-
mals, only minor tumor growth (to 0.28  0.04 cm3)
was observed. The study revealed no significant effect
of CPEwt treatment, but a very efficient anti-tumoral
activity of CPE-Mut3, reflected by reduced tumor
growth (14% compared to control) (Fig. 6A). Hence,
unlike CPEwt, the CPE variant with increased affinity
to Cldn1 binds stronger to PTC cells. This binding is
associated with more efficient tumor cell killing, result-
ing in tumor reduction.
In the PC-9 xenograft model, measurements of TV on
days 11, 14, 18, and 21 after beginning of CPE-adminis-
tration in different treatment groups revealed anti-tu-
moral activity of both CPEwt and of CPE-Mut3,
reflected by respective TVs of 43% and 29% (compared
to vector control treatment, Fig. 6B). Here, CPE-Mut3
exerted only slightly improved anti-tumoral effects than
CPEwt. Thus, intratumoral CPE treatment is able to
reduce TV in lung cancer PC-9 CDX model effectively.
3.8. CPE treatment causes necrosis in thyroid
and lung tumor
Intratumoral injection of CPE variants reduced signifi-
cantly TV of K1 and PC-9 xenograft models. HE
staining revealed a small amount of 5–10% of necrotic
Fig. 6. Effect of recombinant CPE treatment on tumor growth. K1 cells (A) or PC-9 cells (B) were injected s.c. into female NOG mice.
When tumors reached a mean volume of 0.14 cm3, animals were randomized into treatment groups and in vivo recombinant CPE
intratumoral application was performed. Thus, CPEwt or CPE-Mut3 was applied by 10 injections (arrow heads) (0.04 lg CPElL1 0.9%
NaCl, daily). (A) K1-TV in the group, treated with CPE-Mut3, was 25% compared to those treated with vector control or CPEwt. CPEwt did
not affect the K1 cells and therefore did not reduce the TV (i) due to the absence of Cldn3 and Cldn4 in these cells, the main receptors of
CPEwt, and (ii) due to its inability to strongly interact with Cldn1. n = 4–5. (B) PC-9- TV in the group, treated with CPEwt or CPE-Mut3, was
only 58% or 47%, respectively, of those treated with vector control. n = 5. (C) Histological analysis of HE-stained K1 and PC-9 xenograft
tumors showing the different degrees of tumor necrosis. Necrotic areas are contoured with black line. Representative photomicrographs are
shown. Lower panels display higher magnification of the blue boxes. (D) Quantification of necrotic area in K1 tumor. (E) Quantification of
necrotic area in PC-9 tumor. Quantification of necrotic area was performed with 2 tumors, each 3 sections, in total 6 areas per group.
Statistical analysis was performed with two-way ANOVA with Bonferroni multiple comparisons (A, B) and Kruskal–Wallis test with Dunn’s
multiple comparison test (D, E) significant vs vector control (at the same concentration) **P < 0.01; ***P < 0.001; ****P < 0.0001.
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areas of K1 tumors treated with vector control and
CPEwt, whereas CPE-Mut3 application increased
necrotic areas of K1 tumors to approximately 40%
(Fig. 6C,D). In PC-9 tumors, necrotic areas of vector
control treated mice were approximately 23% and ele-
vated to 51% and 63% by CPEwt and CPE-Mut3
application, respectively (Fig. 6C,E). Taken together,
the in vivo data indicate that CPE treatment reduces
tumor growth by induction of necrosis.
In thyroid and lung tumor xenograft models,
immunostaining of claudins and ZO1 did not reveal a
junctional localization, pointing to absence of intact
TJ. In thyroid xenograft model, the analysis showed
strongest CPE and weakest Cldn1 signals in CPE-
Mut3-treated samples (Fig. S3). For lung xenograft
model CPEwt and CPE-Mut3 treatment, the immunos-
tainings did not reveal a clear change in expression
and distribution of Cldn3, Cldn4, and Cldn7 (Fig. S3).
4. Discussion
In this study, we used structure-guided mutagenesis of
CPE to enable for the first time cytotoxic targeting of
tumors expressing Cldn1 or Cldn5 to which CPEwt
does not bind considerably. As a proof of principle,
we showed in vitro and in vivo that claudin-binding
properties of CPE can be shifted (a) to expand use of
CPE to targeting of Cldn1-expressing thyroid tumors
and (b) to potentially reduce CPE side effects by
matching the binding properties of CPE to the claudin
expression profile of particular carcinoma types.
This study aimed to overcome the restriction of the
promising CPE treatment to tumors expressing only
receptors for CPEwt (Cldn3, Cldn 4, Cldn6, Ben-
David et al., 2013; Kominsky et al., 2007; Kominsky
et al., 2004; Liang et al., 2017; Michl et al., 2001; San-
tin et al., 2005; Walther et al., 2012). We adapted the
CPE binding properties to other claudins according to
the expression profile of different carcinomas. In par-
ticular, binding to Cldn1 expressed in NSCLC (Jung
et al., 2009; Sun et al., 2016) and thyroid cancer
(Zwanziger et al., 2015) was intended. The role of
Cldn1 in follicular type of thyroid cancer was well
described (Zwanziger et al., 2015). However, for PTC,
the most common type of thyroid cancer, the Cldn1
expression, and its role in pathogeny are currently
poorly characterized. In this study, we concentrated on
PTC since this is the most common type of all thyroid
cancers.
First, we verified if model-guided variants of cCPE
– the nontoxic claudin-binding domain of CPE – were
able to interact with Cldn1 to Cldn7. cCPE-Mut3 with
increased binding to Cldn1 was chosen as the most
promising candidate for PTC cells’ eradication. Its
additional ability to interact with Cldn5 is of advan-
tage for potential NSCLC treatment, since NSCLC is
characterized by upregulation of several claudins
including both Cldn1 and Cldn5 (Paschoud et al.,
2007).
Consequently, Mut3 and, as comparison, Mut4 –
which was previously shown to improve cCPE binding
to Cldn1 and Cldn5 – were introduced into cytotoxic
full length CPE and showed identical claudin speci-
ficity as corresponding cCPE variants. In contrast to
CPEwt, CPE-Mut3 and CPE-Mut4 were cytotoxic for
Cldn1-overexpressing but not for native HEK cells.
This finding demonstrated the ability of novel CPE
variants to specifically target Cldn1-expressing cells.
Furthermore, in contrast to CPEwt, CPE-Mut3 was
cytotoxic for K1 thyroid cancer cells expressing
endogenous Cldn1. For PC-9 lung cancer cells that
express multiple claudins, apart from CPE-Mut3 also
CPEwt and CPE-Mut4 mediated cytotoxicity. Finally,
claudin-specific cytotoxicity was confirmed in vivo on
CDX models of PTC (K1 cells) and of NSCLC (PC-9
cells). For the first time, CPE was used to successfully
reduce growth of lung tumors (PC-9 cells) and its
Mut3 enabled efficient Cldn1-directed reduction of
PTC (K1 cells) growth.
Using the same approach of structure-guided muta-
genesis, we also generated CPE-Mut9 and CPE-Mut10
which enabled efficient Cldn5- and Cldn4-directed
cytotoxicity, respectively (Fig. S1). Thus, CPE variants
with claudin-binding properties matching to the clau-
din expression profile of the targeted tumor type have
a potential to maximize tumor cell eradication and
minimize side effects on normal claudin-expressing
cells.
In several studies, high claudin specificity of anti-
claudin antibodies (Cldn1, Yoda et al., 2014; Cldn4,
Silva et al., 2017; Cldn5, Hashimoto et al., 2017; and
Cldn18.2, Singh et al., 2017) was used for cancer cell
targeting. However, recombinant CPE variants as anti-
tumoral tools have several advantages over anti-clau-
din antibodies’ application: (a) cost-effective bacterial
production of CPE, (b) ability to adjust CPE, by direc-
ted structural modification to target several claudin
subtypes and thereby target higher number of claudin
molecules, causing faster and more severe eradicating
effect, and (c) in CPE, the claudin-targeting and effec-
tor (toxic) domains are already natively combined,
whereas for other immunotoxins and antibodies target-
ing and toxicity have to be mediated independently.
Moreover, CPE can be applied by cost- and labor-
effective nonviral in vivo gene transfer (Walther et al.,
2012). This results in CPE production in target cells,
272 Molecular Oncology 14 (2020) 261–276 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Targeting thyroid & lung cancer by modified enterotoxin A. Piontek et al.
causing direct cell killing further enhanced by a toxin-
mediated bystander effect. The claudin specificity and
dependency of the cytotoxicity mediated by CPE
expressed after gene transfer in mammalian cells was
demonstrated previously (Pahle et al., 2017; Walther
et al., 2012). In the current study, gene transfer of
CPE variants mediated a similar toxicity on the
NSCLC model in vitro (PC-9 cells) as the recombinant
protein (Fig. 5D,E). Thus, the suicide gene transfer
approach can be broadened to CPE variants. How-
ever, here we applied recombinant CPE for in vivo
experiments, since this enabled better control of CPE
concentration.
Intratumoral in vivo application of recombinant
CPE did not induce general toxin-associated side
effects in PC-9 and K1 xenograft models bearing mice,
supporting its great therapeutic potential (Kominsky
et al., 2007). However, use of CPE for tumor therapy
is restricted by the fact that CPE-binding claudins are
expressed in numerous tissues and, thereby, there is
risk of unwanted cytotoxic damage of normal cells.
Nevertheless, most tumor cells are assumed to be more
sensitive to CPE than differentiated epithelial cells due
to (a) overexpression and (b) higher accessibility of
claudins caused by extrajunctional mislocalization of
the molecules (Corsini et al., 2018; Eichner et al.,
2017) (Fig. S3). In contrast, for example, in colono-
cytes, claudin accessibility, and in turn CPE-mediated
tissue damage, is strongly limited (Eichner et al.,
2017). However, better restriction of CPE-mediated
cytotoxicity to tumors might be achieved by use of
CPE variants with a claudin-subtype specificity opti-
mized to match the claudin (over-) expression profile
of defined carcinomas. Nevertheless, extent of side
effects due to CPE binding to claudins outside tumors
has to be investigated in future in vivo studies with
CPE variants.
A potential immune response against CPE could be
addressed, for instance, (a) by subsequent use of cyto-
toxic cCPE-PSIF (protein synthesis inhibitory factor)
fusion proteins (Ebihara et al., 2006) or (b) structure-
based modification of surface residues of CPE outside
of the claudin-binding region.
5. Conclusions
In summary, we showed that CPE can be modified by
structure-guided mutagenesis to match the binding
properties of CPE to the claudin expression profile of
particular carcinoma types. We thereby enabled, as
proof of principle, Cldn1-directed cytotoxic targeting
of thyroid tumors. The results suggest use of
CPE-based biologics for eradication of claudin-overex-
pressing cancers in a novel cross-entity approach.
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